TerminatedNCT04684394
A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration
PHASE2 · 50 planned enrolment
- Countries listed
- 1
- Registry update
- October 31, 2022
immortal.lifeTrial registrations containing the exact intervention label GEM103.
No aliases or equivalent products have been inferred.
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →PHASE2 · 50 planned enrolment
PHASE2 · 62 planned enrolment
PHASE1 · 12 planned enrolment